# Contact Script Retatrutide — corrections, citation queries, editorial

> Contact the Script Retatrutide editorial brief for corrections, citation queries, or editorial feedback. This site does not prescribe, dispense, or facilitate access to retatrutide and cannot answer individual medical questions.

We read every message. We do not answer individual medical questions and we do not facilitate access to retatrutide.

## What we respond to

We respond to messages about three things. First, corrections — if a quantitative claim on the site does not match the cited source, or if newer published evidence has overtaken a statement, please tell us and link the source. Second, citation queries — if a reference is broken or a DOI is wrong, we want to know. Third, editorial feedback — clarity, tone, structure, omissions. We read everything.

We are a small editorial project, not a help desk. Response time is best-effort.

## What we cannot answer

We cannot help you obtain retatrutide. We cannot refer you to a prescriber or a compounding pharmacy. We cannot evaluate whether a particular vendor's material is genuine, pure, or safe — and as the brief explains, the FDA's September 2025 enforcement made clear that retatrutide distributed outside the sponsor's clinical-trial supply chain is, by federal definition, an unapproved new drug. We also cannot answer individual medical questions about your situation; that is what a qualified clinician is for.

If you are interested in joining a retatrutide clinical trial, the active trials are listed on ClinicalTrials.gov; enrollment is handled by the individual trial sites, not by us.

## How to reach us

Use the contact form below. Messages are routed to the editorial inbox. We do not publish a phone number and do not maintain a clinic address — see /about for why.

If your message is about a specific quantitative claim on the site, the most useful thing you can include is the page URL, the exact sentence in question, and a link to the source you are pointing us to. That cuts the back-and-forth and lets us update faster.

## Press and academic queries

Journalists, researchers, and editors covering the incretin pipeline are welcome to reach out. We can confirm citations, share the underlying source PDFs where licensing permits, and discuss the editorial approach used in the brief. We do not, however, comment on the commercial pipeline of any sponsor or speculate about NDA timelines beyond what is stated on the public ClinicalTrials.gov registrations.

---

An independent editorial digest of peer-reviewed research — not a clinic, not a prescriber, not a vendor.